2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Biological activity
Description
CAS NO.：1353550-13-6 Product Name：Olmutinib Synonyms：N-[3-[[2-[[4-(4-Methyl-1-piperazinyl)phenyl]amino]thieno[3,2-d]pyrimidin-4-yl]oxy]phenyl]-2-propenamide;Olmutinib;HM61713;BI 1482694;HM71224;CHL9B67L95;Olmutinib (HM61713, BI 1482694);N-(3-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)thieno[3,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide;N-[3-[2-[4-(4-methylpiperazin-1-yl)anilino]thieno[3,2-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide;Olmutinib [INN];2-Propenamide, N-[3-[[2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]thieno[3,2-d]pyrimidin-4-yl]oxy]phenyl]-;2-Propenamide, N-(3-((2-((4-(4-methyl-1-piperazinyl EINEC: Molecular Formula：C26H26N6O2S Molecular Weight：486.5886
Target:
In Vivo
In Vitro
Olmutinib potently inhibits EGFR in HCC827 cells expressing EGFRDEL19 (IC50=9.2 nM) and H1975 cells expressing EGFRL858R/T790M (IC50=10 nM). In contrast, the IC50 of olmutinib against cells expressing EGFRWT is 2225 nM[1].
Kinase Assay
Cell Assay
Animal Administration
References
[1]. Kim ES, et al. Olmutinib: First Global Approval. Drugs.?2016 Jul;76(11):1153-7.
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
